Overview

Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-12
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
Phase:
PHASE3
Details
Lead Sponsor:
Applied Biology, Inc.
Collaborators:
Daniel Alain, Inc.
Follea International Limited